|
Clinical Diagnostics
1. SARS Detection | 2. HBV Detection| 3. Legionella | 4. Dengue Fever Detection | 5. Chromosomal Aneuploidy Detection | 6. EV71
2. HBV Detection
| Hepatitis is a general term for inflammation of the liver caused by a group of unrelated viruses. To date, six major subtypes of hepatitis are known (A, B, C, D, E and G). About 50 million new cases of hepatitis B are diagnosed annually. The prevalence of chronic hepatitis B infection is high (>8%) in all socioeconomic groups in certain areas including China, Korea, Indonesia and the Philippines (Source: CDC). Hepatitis B virus (HBV) is a blood-borne pathogen belonging to the hepadnavirus family and can cause serious liver disease. Determining HBV DNA levels in HBV patients and suspected HBV carriers allows monitoring of antiviral therapy and also providing a HBV DNA quantity range to identify chronic HBV carriers.
Lamivudine is a nucleoside analogue with potent inhibitory effects on HBV polymerase activity. Increasingly, doctors are prescribing lamivudine as the initial treatment because it has few, if any, side effects. However, prolonged therapy of chronic hepatitis with lamivudine selects for lamivudine-resistant HBV variants. The most-commonly encountered variants involve amino acid changes in the YMDD motif (at position 552 of the HBV DNA polymerase); the methionine is either replaced by a valine (YVDD) or by an isoleucine (YIDD).
In order to analyze the emergence of lamivudine-resistant HBV variants in patients receiving treatment, restriction fragment length polymorphism (RFLP) of the PCR products generated from a portion of domain C of the HBV polymerase gene is performed. PCR-RFLP permits rapid, simultaneous and low-cost detection of wild type and variants associated with resistance to lamivudine therapy. RFLP is suitable for large-scale screening of this polymorphism in clinical samples but direct sequencing may be used for confirmation if necessary. |
| |
| Product Description |
| The HBV kits, based on PCR techniques, are designed to detect HBV DNA. One HBV kit detects and quantifies HBV viral load using the TaqMan real-time PCR technology. The assay is performed in parallel with the internationally known Viral Quality Control (VQC) HBV DNA panel (CLB, Amsterdam, the Netherlands). The other HBV kit can be used to determine HBV variants; three separate PCR assays are used to amplify three fragments around position 552 of the HBV polymerase gene (using primer pairs developed by HKDNA), under identical PCR conditions to distinguish YVDD and YIDD mutants from the wild type YMDD variants. The amplified products are digested with the kit provided restriction enzymes 1, 2, and 3, and the RFLP patterns are determined by gel electrophoresis. The amplification products derived from the HBV variants produce unique and characteristic digestion patterns, by which the YMDD, YVDD, and/or YIDD variants can be determined. Both HBV kits contain reagents sufficient for 50 reactions. |
| |
| For HBV kit ordering or technical details, please submit an online enquiry or contact us. |
| |
| HBV Detection Kits for Clinical Diagnostic |
| Catalogue No. |
Item (*50 Reactions/Kit) |
Kit Manual |
| C02-01-1114 |
HBV mutant (YMDD) test kit (RFLP Technology)
|
|
| C02-01-1115 |
HBV viral load test kit (real-time PCR technology) |
- |
|
|
| |
|
